Hemab ApS
8
4
6
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
A Study of Bleeding and Treatment in Participants With Von Willebrand Disease
Role: lead
A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency
Role: lead
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Role: collaborator
A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia
Role: lead
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
Role: lead
The Lived Experience of People With Von Willebrand Disease
Role: collaborator
Are Uterine Fibroids Pro-thrombotic?
Role: collaborator
The Experiences of People Who Live With Glanzmanns Thrombasthenia.
Role: collaborator
All 8 trials loaded